74.07% of retail investor accounts lose money when trading CFDs / Spread betting with this provider.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74.07% of retail investor accounts lose money when trading CFDs / Spread betting with this provider. You should consider whether you understand how CFDs / Spread betting work and whether you can afford to take the high risk of losing your money.
The vast majority of retail investor accounts lose money when trading CFDs / Spread betting with this provider.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The vast majority of retail investor accounts lose money when trading CFDs / Spread betting with this provider. You should consider whether you understand how CFDs / Spread betting work and whether you can afford to take the high risk of losing your money.
header_logo
Language
    rch
    Client Portal
    Client Portal
    Open account
    Start trading
    rch

    Astrazeneca share price gets a COVID-19 vaccine boost

    It might be expected that in the middle of a pandemic, pharma stocks of all shapes and sizes will be in positive focus. To some extent this has been the case for the Astrazeneca share price, especially with hopes regarding a COVID-19 vaccine.
    However, having hit £10 plus high in July, the Astrazeneca share price has clearly been in consolidation mode, as investors look for fresh fundamental drivers. Ironically, the potential driver of growth, COVID-19, appears to have been something which has recently undermined Astrazeneca shares.

    Learn more about shares trading with us

     

    COVID-19 disruption for the Astrazeneca share price

    The counter-intuitive reason for the negative impact on Astrazeneca shares from the pandemic, is that COVID-19 disruption in hospitals and clinics means that diagnoses that led to drug prescriptions are being reduced. This has shown up in the latest Q3 from Astrazeneca where key fundamental metrics have either been down, or less than expected.
    For instance, product sales came in at 7% rather than 9% the previous quarter, revenues up 3% down from 11%. Indeed, oncology, respiratory and asthma treatment sales all dropped in Q3.

     

    Astrazeneca shares vaccine hopes in limbo

    All of this explains why the Astrazeneca share price remains some 15% off the highs of the year. This is even though the AZN share price has clearly been supported by its high profile COVID-19 initiative with Oxford University.
    However, although the vaccine was due to be ready to combat the pandemic even as soon as the current second wave, it remains in limbo. Vaccines are literally on ice - waiting on clinical trials results and emergency approval. Ironically, the clinical trials were impacted by a lack of COVID-19 patients during the summer. So 30 million vaccines by the end of September has become 4 million by the end of the year.

     

    Maintained guidance for Astrazeneca shares

    It would be wrong to say that there are new drivers for Astrazeneca shares in the near term. For the Astrazeneca share price it is the new blockbusters who are the real catalysts of future growth, and in this respect recently approved prostate cancer treatment Lynparza and diabetes drug Forxiga.
    Therefore despite the COVID-19 vaccine delay, and pandemic disruption, the Astrazeneca shares pipeline has allowed the company to maintain full year guidance. Total revenue expected to increase by a high single-digit to a low double-digit percentage and core earnings per share expected to increase by a mid- to high-teens percentage. Given the volatility in the environment for AZN shares, such guidance remains impressive.

     

    How to trade shares with ATFX

    Looking to trade Astrazeneca shares and other major company shares? Open a live or demo account with ATFX to get up to speed. Start trading now to benefit from competitive spreads, high-quality trade execution, and no commission.
    1. Register for an account or log in to your existing account

    2. Open MT4 either on your desktop or mobile

    3. Search for Astrazeneca shares in the market watch or symbols window

    4. Choose your position size

    5. Hit buy or sell, and then confirm the trade

     

    AZN share price: daily chart

    Although the stock market cliche of “elephants don’t gallop” has some truth to it, for AZN shares we have seen strong momentum over much of 2020. This was particularly the case from March to July with the move from £6 to £10. It would appear that the story of October for the Astrazeneca share price was a double bear trap from below £8. This is something which could leave it well placed to retest the July peak towards the end of 2020, especially while the £8 level is held.

    Daily chart showing Astrazeneca share price daily movements for 2020

     

    Looking for a great trading platform, look no further. MetaTrader 4 is the world's most popular trading platform for a reason.

    It offers a host of functionality that will boost your trading experience. From advanced indicators to automatic trading as well as alerts and trade signals.

    Last Updated: 09/11/2020

    This market commentary and analysis has been prepared for ATFX by a third party for general information purposes only. Any view expressed does not constitute a personal recommendation or solicitation to buy or sell as it does not take into account your personal circumstances or objectives, and should therefore not be interpreted as financial, investment or other advice, or relied upon as such. You should therefore seek independent advice before making any investment decisions. This information has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. We aim to establish and maintain and operate effective organisational and administrative arrangements with a view to taking all reasonable steps to prevent conflicts of interest from constituting or giving rise to a material risk of damage to the interests of our clients. The market data is derived from independent sources believed to be reliable, however we make no representation or warranty of its accuracy or completeness, and accept no responsibility for any consequence of its use by recipients. Reproduction of this information, in whole or in part, is not permitted.


     

    Recent news

    Indices Shares share price earnings stocks Cineworld
    Cineworld share price could slump to 33 from 44.79 as cash reserves run out

    Cineworld share price had a stellar return of 331.23% from its October low to November hig...

    Shares share price earnings stocks Topps Tiles
    Topps Tiles share price hit by early 2020 profits warning

    It can be said that there are few stocks and sectors outside the pharma area who can prove...

    Shares share price earnings stocks iQIYI
    Bullish sentiment for the iQIYI share price

    It is usually the case that even with the most bullish of stocks and where market sentimen...

    GBPUSD XAUUSD
    GBPUSD could breach monthly high & reach 1.34 on UK inflation turning up

    This morning, the GBPUSD leapt higher by 20 pips as the latest ONS inflation figures showe...

    Shares share price earnings stocks JD
    Months of outperformance for the JD share price

    One of the best stock market rules regarding the share price of companies in the wake of r...